Kornimate/medical-research-clean huggingface dataset:
a biological atlas of severe obesity (biological tissue collection)

Conditions: Obesity; Glucose Intolerance; Diabetes

Summary: type 2 diabetes and obesity are both multifactorial diseases resulting from gene-environment interactions. however, this interaction, as well as the specific effect of each polymorphism, remains poorly understood. we now proposed a prospective cohort study to improve our understanding of the influence of phenotypic characteristics on gene expression in tissues involved in glucose and/or lipid metabolism by collecting different biological samples.

type 2 diabetes (t2d) is a disease commonly associated with obesity, which is an important risk factor for this condition. more than 80% of the diabetic subjects are obese. by analogy with the metabolic syndrome, the close association between obesity and t2d justifies the recognition of a new disease entity named by the neologism "diabesity". this study will examine the contribution of different genetic variants on "diabesity" development, by integrating multiple genomics approaches (linkage analysis on whole genome, transcriptomics and bioinformatics) and analysis of biological pathways in relevant animals models and humans.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * indication of abdominal surgery requiring a laparotomy or laparoscopy for bariatric surgery, cholecystectomy, or parietal surgical * phenotype corresponding to one of the following four cases : 1. body mass index ≥ 35 kg/m2 and diabetes defined by a fasting blood glucose ≥ 7 mmol/l and/or ≥ to 11.1 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route) 2. body mass index ≥ 35 kg/m2 with intolerance glucose defined by a fasting blood glucose\> 6 mmol/l and \ 7.8 mmol/l and \<11.1 mmol/l , 120 minutes after ingestion of glucose (hyperglycemia caused by oral route) 3. body mass index ≥ 35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/l and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route) 4. body mass index \<27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/l and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route) 5)27 \<body mass index \<35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/l and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route) exclusion criteria: * unable to receive clear information * refusal to sign the consent form * pathology associated judged by the surgeon, may increase the risk of adverse events related to sampling tissue

Keywords: obesity surgery genetic expression collection of samples
relaxation guided imagery for treatment of pain in parkinson's disease

Conditions: Parkinson's Disease

Summary: parkinson's disease patients may have severe non-motor symptoms. a common and troublesome non-motor symptom is pain. currently these symptoms are treated with medication with limited success. our study aims to determine whether relaxation guided imagery can alleviate pain in parkinson's disease patients.

parkinson's disease patients with severe pain without dementia will participate in this study aimed to examine a possible beneficial effect of relaxation guided imagery on pain. this will be a phase i, controlled, single blind and randomized efficacy study in 2 parallel groups. the study will include a baseline assessment of pain severity where after the intervention group will undergo relaxation guided imagery and the control group will listen to relaxing music. after these relaxation session patients will receive a cd with either relaxation guided imagery or relaxing music to listen to at home. pain severity will be recorded for the following 6 weeks.

Eligibility criteria:
inclusion criteria: * patients with idiopathic parkinson's disease suffering from significant pain. exclusion criteria: * dementia * hearing impairment

Keywords: imagery pain depression non-motor
a therapeutic protocol in previous failed art patients with high total nk cells

Conditions: Unexplained Infertility

Summary: patients with previous failed art cycles with high peripheral nk cells will be divided into 2 groups: one group of patients with previous failed art cyles will undergo standard treatment but the other group will have in addition lipid emulsion \&prednisolone \& lmwh

patients with previous failed art cycles with high peripheral nk cells will be divided into 2 groups: one group of patients with previous failed art cyles will undergo standard treatment but the other group will have in addition lipid emulsion begin in the cycle before embryo transfer \&prednisolone begin with the start of lipid emulsion \& lmwh begin with the day of et

Eligibility criteria:
inclusion criteria: * patients with high peripheral nk cells \> 10% unexplained infertility cases cases with endometriosis exclusion criteria: * uterine factors poor responders\< 3 mii oocytes severe male factor \& azospermia
antiresorptive effects of a 6-m treatment course with ibandronate plus supplementation of vitamine d and calcium in central america

Conditions: Osteoporosis

Summary: ibandronate is a third-generation biphosphonate with recognized antiresorptive efficacy by several international, randomized, double-blind, controlled trials. these studies have not included patients from central america, to the best of our knowledge. therefore, this open-label, uncontrolled study, was set out to assess the clinical effects of a 6-m treatment course with ibandronate plus vitamine d and calcium on bone mineral density and health-related quality of life.


Eligibility criteria:
inclusion criteria: * women with a diagnosis of osteoporosis of at-risk * have a medical indication to receive ibandronate+vitamine d+calcium exclusion criteria: * osteoporosis due to secondary causes

Keywords: osteoporosis ibandronate vitamine d calcium bone mineral density health-related quality of life
heart timing - heart transplantation imaging

Conditions: Heart Transplant Failure and Rejection; Magnetic Resonance Imaging

Summary: the cardiac allograft rejection (car) and cardiac allograft vasculopathy (cav) significantly affect the prognosis of patients after heart transplantation. the aim of the present study is to investigate and differentiate the adaptive and pathological cardiovascular changes after heart transplantation using different modalities. the investigator's main purpose is to define the role of the cardiovascular imaging methods and biomarkers in the early diagnosis of car and cav.

1. 12-lead ecg - resting standard 12-lead digital ecg will be recorded. extended analysis will be performed according to the latest recommendations. 2. holter ecg - 24 hour holter ecg will be recorded. extended holter ecg analysis will be performed. 3. life quality questionnaire, patient history - detailed questionnaire about personal and family history, general symptoms and life quality. 4. laboratory biochemical examination - besides the regular routine laboratory parameters, several specific parameters are planned to be measured, such as cardiac biomarkers. 5. endomyocardial biopsy 6. detailed transthoracic echocardiography including strain analysis and 3d measurement 7. detailed cardiac magnetic resonance (cmr) examination 8. coronary imaging - invasive coronarography and intravascular ultrasound (ivus) and/or optical coherence tomography (oct) 9. invasive pressure measurement - measurement of coronary flow reserve (cfr) and microcirculation resistance index (imr)

Eligibility criteria:
inclusion criteria: * first heart transplantation exclusion criteria: * cardiogenic shock on/after day 28 after heart transplantation * lack of consent * lack of cooperation
ixekizumab concomitantly administered with tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight

Conditions: Psoriasis; Obesity

Summary: the main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.


Eligibility criteria:
inclusion criteria: * have a diagnosis of moderate-to-severe plaque psoriasis (pso) for at least 6 months. * have both a static physician's global assessment (spga) score of ≥3 and a psoriasis area and severity index (pasi) ≥12. * have ≥10% body surface area (bsa) involvement. * have obesity, body mass index of ≥30 kilograms per meter squared (bmi ≥30 kg/m²) or overweight (bmi ≥27 to \<30 kg/m²) in the presence of at least 1 of these weight-related comorbid conditions (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or t2dm). exclusion criteria: medical conditions * have type 1 diabetes mellitus (t1dm). * have insulin-treated type 2 diabetes mellitus (t2dm). * have a prior or planned surgical treatment for obesity. * have a family or personal history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia (men) syndrome type 2. * have active, or a history of inflammatory bowel disease (crohn's or ulcerative colitis). * have a diagnosis or history of malignant disease within the 5 years prior to randomization, with the following exceptions: * basal cell or squamous epithelial carcinomas of the skin that have been resected, with no evidence of metastatic disease for 3 years. * cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to randomization. * have serious disorder or illness other than pso. * have a history of chronic or acute pancreatitis. * have any prior use of ixekizumab or tirzepatide. * have a previous failure or intolerance to an interleukin 17 inhibitor (il-17i) or glucagon-like peptide 1 (glp-1) receptor agonists.
long-term prednisone use for end-stage heart failure

Conditions: Heart Failure; Hyperuricemia

Summary: patients with advanced (accf/aha stage d) heart failure and hyperuricemia have high one-year mortality. currently, there was no evidence-based therapy such as mechanically assisted circulatory support available in china. the investigators found glucocorticoid treatment such as prednisone could improve cardiac performance, potentiate renal responsiveness to diuretics in such patients. therefore, it could be used as bridge therapy to help ace inhibitors or beta blocker titration. with its help, most of the patients with stage d heart failure could be titrated to higher dose of ace inhibitors and beta blockers during hospitalization. however, the efficacy of long-term, low-dose of prednisone use in such patients with limited life expectancy remain unclear. therefore, the investigators designed this study to observe whether putting low-dose of prednisone on the patients with stage d heart failure for long term could further improve their survival. all patients will receive prednisone treatment during hospitalization and receive maximum tolerated guideline-directed medical therapy (gdmt). after discharge from hospital, the patients will be randomized to receive long-term, low-dose prednisone treatment or standard gdmt.


Eligibility criteria:
inclusion criteria: * repeated (\>2) hospitalizations or ed visits for hf in the past year * inability to exercise including exertion limited, exertion intolerance, resting symptoms or inotrope dependent * left ventricular ejection fraction ≤35% * serum uric acid level ≥500μmol/l * received prednisone treatment during hospitalization period and and more 5 of the followings 1. progressive deterioration in renal function (e.g., rise in bun and creatinine) 2. weight loss without other cause (e.g., cardiac cachexia) 3. intolerance to ace inhibitors due to hypotension and/or worsening renal function 4. intolerance to beta blockers due to worsening hf or hypotension 5. frequent systolic blood pressure \<90 mm hg 6. recent need to escalate diuretics to maintain volume status, often reaching daily furosemide equivalent dose \>160 mg/d and/or use of supplemental thizide therapy 7. progressive decline in serum sodium, usually to \<133 meq/l 8. gastrointestinal symptoms (abdominal discomfort, nausea, poor appetite), disabling ascites, or severe lower-extremity edema exclusion criteria: * any condition (other than heart failure) that could limit the use of prednisone * any concurrent disease that likely limits life expectancy; * active myocarditis, or an hypertrophic obstructive or restrictive cardiomyopathy; * myocardial infarction, stroke, unstable angina, or cardiac surgery within the previous 3 months; * indication for hemodialysis * uncontrolled systolic blood pressure \> 160 mmhg * complex congenital heart disease * poorly controlled diabetes
high power short duration ablation for paroxysmal af with high density multi directional mapping (lowe af hd study).

Conditions: Atrial Fibrillation

Summary: the lowe af hd is a prospective, single-center, non-randomized study to assess safety, efficacy, acute and long-term outcome data of a specific ablation approach as treatment of paroxysmal atrial fibrillation.

pulmonary vein isolation using radiofrequency (rf) ablation is acknowledged used treatment strategy for atrial fibrillation, many different approaches are recently implemented. the specific approach used in this study includes: * multi-directional high-density mapping * high power - short duration settings * contact force sensing ablation catheter the aim of lowe af hd is to assess the acute safety and success rate of this approach and also the long-term outcome assessed by atrial recurrences arrythmias collected by an implantable loop recorder.

Eligibility criteria:
inclusion criteria: * consecutive and unselected patients with a class i-iia indication for ablation of paroxysmal af * 18 years and older. * able and willing to provide written informed consent prior to any clinical investigation related procedure * able and willing to complete all required study procedures through 12 months * life expectancy less than 12 months exclusion criteria: * persistent or long-standing persistent af * presence of thrombus in left atrium and left atrium appendage * mi, cabg or pci within preceding 3 months * left atrial diameter \> 5.0 cm * lvef \< 35% * nyha class iii or iv * previous atrial fibrillation ablation procedure with high density and high-power short duration approach * previous tricuspid or mitral valve repair surgery

Keywords: af high power - short duration ablation high density mapping
triggers and risk factors to develop a reversible cerebral vasoconstriction syndrome

Conditions: Reversible Cerebral Vasoconstriction Syndrome

Summary: this study will be the first to evaluate the role played by potential precipitating factors and risk factors in reversible cerebral vasoconstriction syndrome (rcvs) through of prospective selection of carefully characterised patients and controls. the impact of these factors on the prognosis will be evaluated through a follow-up assessment of patients. our study will include the formation of a clinicoradiological database and a biobank (plasma, cerebro-spinal fluid, dna) which will be the tools of a future large multicentre study on rcvs.

introduction : reversible cerebral vasoconstriction syndrome (rcvs) combines headaches and segmental constriction of cerebral arteries that resolves within 3 months. it is the most recurrent reason of cerebral arteriopathy in people under 70 and of thunderclap headache in absence of aneurysmal subarachnoid haemorrhage. objectives : * principal: identify rcvs's precipitating factors * secondary: 1. determine if migraine, anxiety, depression are risk factors of rcvs. 2. determine the role of precipitating factors and risk factors on the rcvs's prognosis in short, medium and long term. 3. start a formation of a large clinicoradiological database and a biobank (plasma, cerebro-spinal fluid, dna). methodology : monocentric analytic observational 'case - control' study with prospective inclusion of cases in a follow-up cohort. this type of study is nevertheless considered interventional because we are collecting additional blood and csf samples to constitute a biobank.

Eligibility criteria:
inclusion criteria: * for the patients * men and women of 18 and more years old * taken care in the chu of montpellier * diagnosis of svcr or svcr without visible vasoconstriction makes in 14 days preceding the inclusion * according to the consensual criteria of diagnosis and those of the international classification of the headaches ichd-3 * informed consent and writes for the participation in the study * for volunteers * men and women of 18 and more, mated in the cases on the sex and the age * patients with an acute pathology not neurological and not vascular (for example, eye foreign body) or healthy subjects * informed written consent and for the participation in the study exclusion criteria: * coma, insanity, language barrier or severe aphasia preventing from answering the questions * follow-up considered impossible for 3 months (e.g.: priority associated pathology in the care, the transfer(transformation)) * people placed under legal protection * refusal to participate in the study

Keywords: thunderclap headache
vibrotactile feedback during vestibular therapy

Conditions: Vestibular Disease

Summary: this study evaluates the use of vibrotactile feedback to traditional vestibular treatment protocols. half the patients will have vibrotactile feedback added to their treatment protocols while the other half will undergo traditional vestibular treatment without vibrotactile feedback.

vestibular and balance rehabilitation is an effective way to improve balance for individuals with balance impairments by using the strategies of adaptation, habituation, or substitution. typical vestibular treatment is usually 3 sessions per week for 6 weeks. for people with uncompensated unilateral vestibular hypofunction or bilateral vestibular loss, recovery/adaptation is often incomplete and chronic balance impairments result. vibrotactile feedback (vtf) is a strategy of substitution, or augmentation, to replace disrupted or absent vestibular function. the sensory information replaces disrupted or absent vestibular function to give persons additional signals about their body position in space. real-time vtf applied to the trunk has been shown to decrease postural sway but the long-term benefits of training with vtf on balance and function have not been examined.

Eligibility criteria:
inclusion criteria: * unilateral peripheral vestibular hypofunction * bilateral peripheral vestibular hypofunction exclusion criteria: * confounding neurologic or neuromuscular disorders * pregnancy * inability to stand for 3 minutes * recent lower extremity fracture/severe sprain within the last 6 months * previous lower extremity joint replacement * incapacitating back or lower extremity pain * body too large for equipment

Keywords: vibrotactile feedback vestibular rehabilitation balance
increased crp concentrations in patients admitted to the emergency department with troponin elevation aids to rule out coronary ischemia

Conditions: Myocardial Ischemia

Summary: the investigators hypothesized that the crp/troponin ratio measured in patients presenting to the ed with elevated troponin levels could differentiate between patients with cardiac ischemia and those who present due to a systemic inflammatory or infectious disease. the aim of the study was to determine the necessary crp/troponin ratio required to rule out cardiac ischemia in a large ed population and determine its impact on long-term prognosis.


Eligibility criteria:
inclusion criteria: * all patients admitted to the ed in the period 2016-2019 with ctn level higher than the 99th percentile of ctn concentration in the normal population (\>0.014 nanogram/milliliter). exclusion criteria: * none
surgery before embryo transfer in error (endometrioma related reduction in ovarian reserve)

Conditions: Endometriosis Related Infertility

Summary: this prospective study evaluates the pregnancy results after laparoscopic endometriosis operation in infertile patients with error (endometrioma related reduction in ovarian reserve)

this study consists of two groups. patients will be randomly enrolled into the groups by art (assisted reproductive technology) centre nursery. all patients will sign a consent form about procedure. patients diagnosed with endometrioma (larger than 3 cm diameter) and error (endometrioma related reduction in ovarian reserve - antimullerian hormon \ 10 iu/dl, low response to ovarian hyper stimulation \ 40, with male factor, with undefined adnexal mass, malignity suspicion will be excluded from study. the study group consists of patients who will undergo laparoscopic endometriosis surgery after icsi procedure with freezing all embryos. the patients will wait about 6 months for spontaneous conception, if there is no pregnancy during this period, frozen embryo transfer will be performed. the control group consists of patients who will be performed ivf\&icsi procedure with fresh embryo transfer without surgery. if there is no pregnancy, patients will be operated then. as the primary; result positive b-hcg rates will be compared between groups. in conclusion we will find out whether laparoscopic endometriosis operation improves or worsens the pregnancy results in patients with error.

Eligibility criteria:
inclusion criteria: * presence of endometrioma at least in one ovary, larger than 3 cm diameter * endometriosis related reduction in ovarian reserve (error) * presence of endometriosis related infertility exclusion criteria: * presence of chronic systemic disease * presence of male factor infertility * suspicion of ovarian malignancy or undefined ovarian mass

Keywords: endometriosis laparoscopy infertility ovarian reserve endometrioma
a survey of financial toxicity in rural cancer patients

Conditions: Financial Toxicity

Summary: this project aims to elucidate the prevalence of financial toxicity, identify significant risk factors for toxicity, and understand the burdens of the specific st. johnsbury rural population. these data will drive future, larger studies to investigate how to alleviate the burden of financial toxicity, especially in vulnerable patient populations.

"financial toxicity" refers to a side effect of cancer treatment that is financial in nature, and has become increasingly important to oncologists, patients, and researchers because of its implications in adverse social outcomes for patients. financial toxicity in the context of cancer care is the monetary cost, and subsequent social implications of the cost, on patients undergoing cancer treatment. although financial toxicity for patients undergoing cancer treatment has some research attention, financial toxicity associated with radiation therapy for cancer patients has not. there is preliminary data that has shown that there are two forms of financial toxicity: the direct cost of cancer therapy (medical services) and the indirect costs (gas for travel, lost wages for sick days, etc.). however, the degree of cost and sources have not been fully investigated. specifically, financial toxicity in the context of cancer patients from rural populations (such as those at nccc) has not been fully explored. this project will attempt to understand the salient factors, costs, and magnitudes of financial toxicity in radiation therapy that will allow for more targeted studies to investigate vulnerable patient populations who experience greater financial toxicity. study recruitment temporarily halted due to covid-19.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * undergoing treatment at norris cotton cancer center north, st. johnsbury, vt * current radiation/oncology patient * ability to speak or write in english